🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against increasingly resistant strains of the pathogen, according to scientists.

A Global Public Health Issue

Cases of gonorrhoea are increasing globally, with figures suggesting over 82 million infections per year. Notably increased rates are reported in Africa and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune advancement in the face of growing infection rates, escalating drug resistance and the highly restricted available drugs presently on offer.”

Public health authorities are deeply concerned about the increase in antibiotic-resistant strains. The WHO has classified it as a "high-priority threat". A tracking program showed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Approval

One new antibiotic, also known as a brand name, was authorized by the US FDA in mid-December for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Scientists anticipate that specific application of this new drug will help hinder the development of resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This drug, which is employed against urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a innovative non-profit model for drug creation. The charitable organization GARDP worked alongside the drug firm its industry partner to see it through.

“This approval marks a huge turning point in the management of highly resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Clinical Trial Results and Worldwide Availability

Based on results detailed in a prominent scientific publication, the new drug cured the vast majority of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which uses two antibiotics. The study included over 900 participants from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to register and commercialise the drug in many low-income and middle-income countries.

Doctors treating patients have shared optimism. The availability of a easy-to-administer therapy of this kind is seen as a "revolutionary step" for gonorrhoea control. This is considered vital to lessen the impact of the disease for patients and to prevent the spread of highly drug-resistant gonorrhoea around the world.